Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector For Treatment Of Anemia Associated With Chemotherapy And Chronic Kidney Disease

Amgen (NASDAQ:AMGN) today announced the launch of the Aranesp(R) (darbepoetin alfa) prefilled SureClick(TM) autoinjector for patients with chemotherapy-induced anemia and anemia associated with chronic kidney disease (CKD) in the United States.